Replies to post #412501 on ORIONS Money Stocks

[naturalborninvestor]

HMNY broke MA8, MA34 and MA50 today. CMF and Fast STO turning. Major bullish reversal according by your rules.

[AugustaFriends]

$MNGA .28 break could run to .56 Weekly 8x34 Cross

[TheFinalCD]

https://finviz.com/quote.ashx?t=AMRS

[BottomBounce]

Your whole board is a pump. YOu have the nerve to call me a pumper! I learned from YOU @AugustaFriends

[AugustaFriends]

$PULM break $1.11 could run for 100% low floater after the RS

[AugustaFriends]

$RBZ 1.22 closing strong $1.75 coming soon@!!

[AugustaFriends]

$FLKS watch for .48 breakout Target .78

[AugustaFriends]

$AAU ,67 up 61% in June - next wall is .91 on weekly chart

[AugustaFriends]

50% potential >> $NGD .78 on watch for .87 break with $1.20 Target

[Lone Wolf]

Hey yo...put this in your formula thingy!! http://schrts.co/ekwttkuR . :-)

$PRED

[AugustaFriends]

$FCEL sold all my shares and bought more $SESN

[AugustaFriends]

$NTNX up during pre-market

[AugustaFriends]

$GES 15.04 up during pre-market

[AugustaFriends]

$FUV alert alert by Augustafriends at 3.44

[stock1ace1]

Wter @$2.60 a/h broke 200ma on big news


Alkaline Water To Expand CBD Offering With AQUAhydrate Acquisition; Deal With Mark Wahlberg, Sean ‘Diddy’ Combs, Jillian Michaels !

[stock1ace1]

MARA @$1.02 Broke 50MA ! Look ~> https://finviz.com/quote.ashx?t=Mara

[stock1ace1]

LKCO $1.18 Huge News W/ Ford !

[stock1ace1]

VIVE @.99 **** Round 2 ***** !

[AugustaFriends]

$CPRX in at 2.99 with 5,000 shares

[riskon]

Aloha Augusta

[stock1ace1]

Codx 8.75 *****

[AugustaFriends]

$FRAN alert!!! 2.88

[AugustaFriends]

$STAY Extended Stay America EPS beats by $0.02, beats on revenue


May 6, 2020 4:52 PM ET|About: Extended Stay America, ... (STAY)|By: Niloofer Shaikh, SA News Editor
Extended Stay America (NASDAQ:STAY): Q1 Non-GAAP EPS of $0.07 beats by $0.02; GAAP EPS of $0.03 beats by $0.02.

Revenue of $266.3M (-4.1% Y/Y) beats by $14.14M.

https://seekingalpha.com/news/3570609-extended-stay-america-eps-beats-0_02-beats-on-revenue?utm_campaign=twitter_automated&utm_content=news&utm_medium=social&utm_source=twitter_automated

[stock1ace1]

TUSK $1.20 Breaking out

[AugustaFriends]

Rose Above Upper Bollinger Band today: $CLH $KLXE $SHAG $MOSY $USI $SMMU $OIH $SLB ...

[AugustaFriends]

$TGI $7.49 watch for possible entry on Monday -- looks good longer term- just watch for best possible entry

[AugustaFriends]

Most tweeted Top 10: $VISL $MARK $FRSX $BIOC $IDEX $CAPR $XSPA $NE $KTOV

[stock1ace1]

CYCC $4.78 *** huge breakout coming

[stock1ace1]

NOVN .52 Breakout !!! Its gonna go

[stock1ace1]

IZEA $1.12 Chart it ! Same as gnus setup easy $$

[stock1ace1]

MYOS $1.33 *** Breakout 5 Mill float

[stock1ace1]

MYOS downtrend broke !!

[Sandera]

DD on STCN [NASD] @ 0.55 AMZN like eCom
Steel Connect, Inc. https://www.steelconnectinc.com/


Seriously Underval IMO
Market Cap 34.88M
Shs Outstand 61.82M
Sales 822.40M

https://steelconnectinc.com/ Corporate website

Steel Connect STCN has two wholly owned subsidiaries:
ModusLink Corporation https://www.moduslink.com/

and IWCO Direct. https://www.iwco.com/

DECEMBER 18, 2017 / 3:20 PM / 3 YEARS AGO
Acquisition Of Iwco Direct For $476 Mln In Cash
https://www.reuters.com/article/brief-moduslink-announces-acquisition-of/brief-moduslink-announces-acquisition-of-iwco-direct-for-476-mln-in-cash-idUSASB0BY9S

https://finance.yahoo.com/news/steel-connect-reports-third-quarter-202100502.html

STCN Nine-Month Financial Summary

Net revenue for the first nine months of the fiscal year increased $2.6 million to $618.0 million, compared to $615.4 million for the same period in the prior year.
Gross margin increased 160 basis points to 19.9% for the first nine months of the fiscal year, compared to 18.3% for the same period in the prior year.
Operating income for the first nine months of the fiscal year increased $15.2 million to $23.0 million, compared to $7.8 million for the same period in the prior year.
Net loss for the first nine months of the fiscal year decreased $23.8 million to $4.9 million, compared to a net loss of $28.7 million for the same period in the prior year.
Adjusted EBITDA for the first nine months of the fiscal year increased $11.4 million to $62.1 million, compared to $50.7 million for the same period in the prior year.

STCN

HUGE history:: https://en.wikipedia.org/wiki/Steel_Connect

Steel Connect, Inc. is a company that provides supply chain management services to software companies. During the dot-com bubble, the company, which was then known as CMGI, had a market capitalization of $41 billion and owned the naming rights to the home stadium of the New England Patriots.

Between 1995 and 1999, its stock was the best performing stock in the United States, returning 4,921%.

The company was formerly known as College Marketing Group, CMG Information Systems, CMGI Inc.,

In September 2008, the company changed its name to ModusLink Global Solutions, Inc.[15]

In December 2017, the company acquired IWCO Direct for $476 million in cash.[16]

In February 2018, the company changed its name to Steel Connect, Inc.[17]







ModusLink® builds supply chain and eCommerce infrastructure that fulfills profit potential and propels superior speed to market for small, midsize, and enterprise-level companies all over the world.
Global footprint spans North America, Europe, and the Asia Pacific region

Steel Connect, Inc., through its subsidiaries, provides supply chain and direct marketing services to the consumer electronics, communications, computing, medical devices, software, storage, retail, and other industries. The company offers product configuration and packaging, kitting, and assembly of components and parts into finished goods; and value-added processes, such as product testing, radio frequency identification tagging, product or service activation, language settings, personalization and engraving, multi-channel packaging, and packaging design services. It also provides fulfillment services, including order management, pick, pack and ship, retail compliance, and demand planning services; and content protection and activation, and IP security services, as well as optimizes component and finished goods inventory levels. In addition, it offers operates a cloud-based e-commerce platform, an online buying experience so that products can be purchased, serviced, and delivered worldwide; and provides reverse logistics services that simplifies the returns process for retailers and manufacturers to improve service parts management and the value of returned assets. Further, the company offers direct marketing services comprising end-to-end services for paper-based direct marketing and omnichannel marketing campaign services. The company was formerly known as ModusLink Global Solutions, Inc. and changed its name to Steel Connect, Inc. in February 2018. Steel Connect, Inc.


WHO WE ARE
STEEL CONNECT
Steel Connect, Inc. is a publicly-traded diversified holding company (Nasdaq Global Select Market symbol STCN) with two wholly-owned subsidiaries ModusLink Corporation and IWCO Direct that have market-leading positions in supply chain management and direct marketing.

https://steelconnectinc.com/ Corporate website

STCN
SHOP
AMZN

[Eagle1]

Hello anyone holding aapl calls through the split?

[stock1ace1]

Buy SDOW Inverse of Dow jones .. dow jones forming bearish engulfing !!

[AugustaFriends]

Charts ))) $GTEC 42% $BIMI 38% $RESI 35% $NTZ 34% $MOXC 31% $DXF 29% $RENN 28% $BDR 27%

[stock1ace1]

Brqs $1.12 news out

[WARHAMMER]

AMBO - plugged in, 8 x 34 about to happen very soon

[stock1ace1]

Wimi $6.21 could explode any day

[stock1ace1]

MTP $1.85 Golden Cross loading !

[stock1ace1]

Taop $3.35 ~>best chart of 2021 ~> https://stockcharts.com/h-sc/ui?s=TAOP

[AugustaFriends]

Good Morning All

[stock1ace1]

Uvxy $4.95 ***

[AugustaFriends]

AEI RMO QK ELOX COMS BRQS SNDL CEI PALI

[AugustaFriends]

$BRQS .98 tomorrow should be a great day!! based on odd-even rule

[stock1ace1]

TLRY $16.31 This is huge ~> https://www.marijuanamoment.net/schumer-to-unveil-federal-marijuana-legalization-bill-on-wednesday/

[stock1ace1]

Bsqr $2.98 ~ $3.00 break sends it

[AugustaFriends]

Good morning all

[AugustaFriends]

$ENSC big boom at 6.30 breakout

[AugustaFriends]

$PTPI 1.84 WATCH 1.95 break

[AugustaFriends]

$AGMH 2.20 watch for 2.33 break --- first target 5.35 on 2.61 break

[AugustaFriends]

$AGMH 2.20 watch for 2.33 break --- first target 5.35 on 2.61 break

[AugustaFriends]

$BJDX received an email from a good source BIG News coming soon ;) Target $6 +++

[AugustaFriends]

$TRKA big boom at 1.21 break

[AugustaFriends]

is $MOHO ready

[stock1ace1]

Rhe $2.39 ** 1.8 mill o/s

[stock1ace1]

Pegy $2.40 on ask nice entry buying a few here

[stock1ace1]

Avgr $1.61 **** 5.6 mill o/s

[stock1ace1]

Pegy moving

[stock1ace1]

Pwgy 3.90$ gapper ‘

[stock1ace1]

Pegy***

[stock1ace1]

Pegy watch for 5$ break huge gap

[stock1ace1]

Avgr $1.65 check the chart breakout ready

[AugustaFriends]

$JCSE 2.12 on watch for $2.36 !!!!

[stock1ace1]

Mtc crazyy spread 2.58 x 2.73

[stock1ace1]

Bnso Halted !!

[stock1ace1]

Mtc $2.68 .. 1.8 mill float about to go green

[stock1ace1]

Here we go mtc $2.60 running

[stock1ace1]

Bnso 4.37 going !

[stock1ace1]

Bnso 4.50s

[stock1ace1]

Mtc $2.42 still buying dips

[stock1ace1]

Nvfy .78 * 4 mill float / 6 mill o/s

[stock1ace1]

Mtc about to rip ! $2.54

[stock1ace1]

Baos 1.40 big buys coming in

[stock1ace1]

Bnso $4.49 running 1 mill float

[stock1ace1]

Avct .15 ***Buyout watch company wants to sell news out today !

[stock1ace1]

Nasdaq: AVCT .15 announces changes to its board of directors and management team, along with the launch of a review to explore the sale of the entire business or selected assets.

[stock1ace1]

Gray $1.06 breakout alert

[stock1ace1]

Gray more fills here $.98

[stock1ace1]

Gray breaking out here .98s

[AugustaFriends]

$WVE 3.04 on watch for 3.15 breakout

[AugustaFriends]

$WVE 3.08 watch for a HIT of 3.12 REVERSAL might start

[stock1ace1]

Big buys on chwy just now !

[stock1ace1]

Chwy $33.66 breaking out

[AugustaFriends]

$APE $5.00 watch for $5.35 possible REVERSAL

[stock1ace1]

Pixy 15s hitting wow. So thin

[stock1ace1]

TGL $2.85 buying here bottom alert

[AugustaFriends]

$ME $FUBO $MTC $CRIS for Friday and into next week

https://schrts.co/UHpySMRG

[stock1ace1]

TgL $2.90s breaking here p/m

[stock1ace1]

TGL $3.04 buy confirmed today bottoms in !

[stock1ace1]

RHE golden cross is here crossover 1.7 mill o/s 1 mill floater !!

[stock1ace1]

Sonn Running .22 ! Huge buys

[stock1ace1]

Reb $2.55 a/h

[stock1ace1]

Rebn $2.47 top stock to watch today

[AugustaFriends]

$FRTX 1.86 watch for 1.95 reversal

[stock1ace1]

Bidding $3.01 abeo 3 mill o/s phase 3 coming anyday !

[stock1ace1]

Abeo 3.30 hod bust

[stock1ace1]

Dpsi $6.73

[stock1ace1]

Atxg $2.76 buyers coming in

[stock1ace1]

Alny $202 up big buys coming in

[stock1ace1]

Alny $200 watch for fda news to drop a/h

[stock1ace1]

Alny $202 fda approval news out !-> Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

[stock1ace1]

Mob $1.71 -> 180k float 52% short 4 mill o/s ??

Anyone have any updates on s/s ?

https://www.floatchecker.com/stock?float=Mob

[AugustaFriends]

$MTC 1.24 to 1.39 SLOWLY it will move until one day it will just burst and explode

[AugustaFriends]

$WETG correction 1.36 will be the BIG BIG Breakout -- 8x34 cross in the making!!

[stock1ace1]

Vero .27 ready !! Look at that chart

[stock1ace1]

IBRX $5.41 ***29% short golden cross/Macd pinch look at chart —> https://schrts.co/XwaFwESI

[stock1ace1]

Ibrx $5.52 breaking out

[stock1ace1]

Ibrx $5.56 huge short squeeze coming

[stock1ace1]

Ibrx $6.02 * shorts trapped now !!

[stock1ace1]

Ibrx $5.59 going !

[stock1ace1]

Ibrx running squeeze alert 5.58$

[stock1ace1]

Ibrx $5.60 hod bust !

[stock1ace1]

IBRX $5.69 Squeezing !

[stock1ace1]

Ibrx $5.65 red to green ?

[AugustaFriends]

$FFIE loading here at .53

[AugustaFriends]

$FFIE .57 watch for $.61 BREAKOUT

[stock1ace1]

HOD $21.50 Up 12% *** Hod busting p/m

[stock1ace1]

JFBR $1.40 ** breaking out

[stock1ace1]

JFBR $1.56 gapping premarket here

[stock1ace1]

Jfbr news out running Jeffs' Brands to Expand Sales Beyond Amazon.com into New Leading E-commerce Platforms

[stock1ace1]

Boom JFBR $1.50 break !! 2 mil float pending acquisition still

[stock1ace1]

Jfbr $1.52

[stock1ace1]

SPRC @$1.00 after hrs was just $1.60 news yesterday crazy short attack buying here

[stock1ace1]

Trka .44 break

[stock1ace1]

MEGL $3.00 break watch for halt

[stock1ace1]

FOXO buying some more here .53

[stock1ace1]

SNES $3.99 ** just r/s 610k o/s micro floater could go parabolic today

The reverse stock split will reduce the number of shares of the Company's common stock outstanding from 12,212,950 shares to approximately 610,648 shares

[stock1ace1]

Cano $1.85 buyout offers few weeks ago now way oversold ? Hmmmm

[stock1ace1]

Cano jan 20 $2.50 calls @.35

[stock1ace1]

Cvna 7.07 squeeze alert !

[stock1ace1]

Cvna $7.25 *** Squeezing !!

[stock1ace1]

Taop .70 so thin breakout watch !

[stock1ace1]

Taop .68 tiny float ready

[AugustaFriends]

** Watch alert ** *** $QH 1.48 on watch for huge break at 1.61

[stock1ace1]

AUVI so thin news out —> Disinfection Technology Company Applied UV Announces Strategic Manufacturing and Supply Chain Collaboration with Canon

[stock1ace1]

HLBz .17 about to go green breakout watch

[stock1ace1]

Big buys hitting HLBZ before close

[TheFinalCD]

Reverse split plays Dec 22

$TISI 1-10 FLOAT PRE-SPLIT 45M (.59= $5.90)

$MARK 1-10 FLOAT PRE-SPLIT 95M (.132= $1.32)

$THMO 1-45 FLOAT PRE-SPLIT 34M (.0998= $4.48)

$OP 1-10 FLOAT PRE-SPLIT 29M (.214= $2.14)

$BTCM 1-10 FLOAT PRE-SPLIT 85M (.196= $1.96)

[stock1ace1]

Aqst chart —> https://schrts.co/XZrsNdmI

[stock1ace1]

SINT @9$ Unhalted *****

[AugustaFriends]

$ONCS ** must see chart 8x34dma *** https://stockcharts.com/h-sc/ui?s=ONCS&p=D&yr=0&mn=3&dy=0&id=p78180976632

[stock1ace1]

INLX $4.55 ***Gapping up7% 2 mill float**

BREAKOUT WATCH

https://schrts.co/fmMMySMc

[stock1ace1]

Fwbi $4.75 about to go green micro float

[stock1ace1]

Thanks for the QH alert charts looks primed

[stock1ace1]

Cvkd $2.82 x 3.02 -> .20 cent spread

[AugustaFriends]

$SOBR history of huge spikes to $4 area

[stock1ace1]

Mots $1.14 ** breaks $1.14 will go 4 mill o/s 4 mill float. https://schrts.co/EWdPnpZx

[stock1ace1]

FWBI 800k float 6 red days bounce watch

[AugustaFriends]

$BJDX see chart, actually .81 break will be HUGE with a 1.40 to 1.53 as next TARGET on break of .81 see weekly indicators as BULLISH

https://stockcharts.com/h-sc/ui?s=BJDX&p=W&yr=1&mn=3&dy=0&id=p96705544146

[stock1ace1]

Pshg —> https://finviz.com/quote.ashx?t=PSHG&p=d

[stock1ace1]

Stsa @.94s going breaking 50ma here

https://stockcharts.com/h-sc/ui?s=Stsa

[stock1ace1]

50ma break stsa @.96 here

[AugustaFriends]

$BTBT watch for 1.25 breakout

[AugustaFriends]

$APRN twitter big folks are jumpig in, I bought 20K shares

[AugustaFriends]

$SATX bought 20,000 shares it is ready

[AugustaFriends]

$GSUN Is ready

[AugustaFriends]

Good morning Orions

[AugustaFriends]

$RGTI **alert** watch for .66 BREAKOUT my Target 1.20's

[AugustaFriends]

$GETR in at .26xx for .55 TARGET

[AugustaFriends]

$FOXO bought 12,000 shares at $.36xx

[AugustaFriends]

$FOXO .41 watch for .451 BIG BREAKOUT!!!

[AugustaFriends]

$MMV added 7000 at 1.66 profits from $TIRX -- $MMV could be next !!

[AugustaFriends]

$EFSH I am buying as many as possible under .40 BIG REVERSAL@!!!!

[AugustaFriends]

$ARVL on watch 8x34 daily cross SOON

[stock1ace1]

ALAR $2.88 ** 3 mill o/s running

[stock1ace1]

Crgo $2.22

[AugustaFriends]

$MBOT 2.66 watch for 2.71 -- looks like bottom found - tomorrow we need a green day

[AugustaFriends]

$FOXO .345 very close to LIFTOFF needs a bit more volume, before alerts go out and BOTS kick in buying 10000 shares at a time for every penny....

[AugustaFriends]

$MBOT 2.82 next wall $2.90 with next stop at 3.40

[AugustaFriends]

$TIO must see MACD and FULL STO -- looks primed for a run, the shake of the tree was last week

https://schrts.co/RdyNtSKs

[stock1ace1]

BanL $3.83

[AugustaFriends]

$MRT today could start the REVERSAL needs to break and close above 1.61 today!!

[stock1ace1]

4.29$ zev hod bust watch here

[stock1ace1]

Will COMS break 50ma here @$1.75

[AugustaFriends]

$MF could be over $3 on Monday.

If the $MF ers squeeze this on 3.7 million float.. this stock could be a life changer.

$MF why not $30 plus dream BIG

$UTME $RAD keep a close watch too.

ORIONS won with $TUP $YELL $MF $RAD others last week

[stock1ace1]

Aka $.65 Earning after bell !!!

[stock1ace1]

CTCX $2.95 Going green breakout watch

[stock1ace1]

Wint $1.57 *** Breakout **** !

[stock1ace1]

Big bids in wint @$1.50 loading more

[stock1ace1]

Filled more wint $1.38 here

[stock1ace1]

Another fake wall @3.60 Brsh push!!

[AugustaFriends]

$QBTS 8x34 charts on watch for 1.27 LOOK AT chart

https://schrts.co/QSGRPjPJ

https://schrts.co/RVRpGvKp

[stock1ace1]

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

NVAX $8.30

Source: PR Newswire (US)
Novavax's 2023-2024 season COVID vaccine candidate induced neutralizing responses to emerging subvariants EG.5.1 and XBB.1.16.6 in addition to XBB.1.5, XBB.1.16 and XBB.2.3
Upon regulatory approval, Novavax's COVID vaccine would be the only protein-based non-mRNA vaccine option available in key markets for the fall season
GAITHERSBURG, Md., Aug. 22, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its updated protein-based XBB COVID vaccine candidate induced neutralizing antibody responses to the EG.5.1 and XBB.1.16.6 subvariants in small animal and non-human primate studies. XBB sublineage variants are overwhelmingly responsible for the majority of current COVID cases in the U.S. and European Union.1, 2

"Our data have shown that Novavax's protein-based COVID vaccine induces broadly neutralizing responses against XBB subvariants, including EG.5.1 and XBB.1.16.6," said Filip Dubovsky, President of Research and Development, Novavax. "We have a lot of confidence in our updated COVID vaccine and are working diligently with global regulatory bodies to ensure our protein-based vaccine is available this fall."

Non-clinical data previously showed that Novavax's COVID vaccine candidate induced functional immune responses for XBB.1.5, XBB.1.16 and XBB.2.3 variants, indicating a broad response that could potentially be applicable for forward-drift variants.3 Novavax is in the process of submitting applications for its XBB.1.5 COVID vaccine candidate to regulatory authorities globally.

[stock1ace1]

Ezgo chart -> https://schrts.co/TwvjyNmJ

[AugustaFriends]

$SWIN let's get back to $12

[stock1ace1]

RHE $2.54 low floater

[AugustaFriends]

$AREB .89 watch for .93 breakout

[stock1ace1]

cnxa short cover before close !! -> Connexa Sports Technologies Inc. (NASDAQ: CNXA) (www.connexasports.com) (the “Company”) announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-40. The reverse stock split will become effective on September 22, 2023. The Company’s common stock will begin trading on a post-split basis at the market open on September 25, 2023, under the Company’s existing trading symbol "CNXA", with the new CUSIP number, 831445309. The reverse stock split is part of the Company’s plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.
The reverse stock split was approved by the Company’s stockholders at the Company’s Special Meeting of Stockholders held on September 13, 2023, to be effected in the discretion of the Company’s board of directors within approved parameters. The final ratio was approved by the Company’s board of directors on September 13, 2023.

The reverse stock split reduces the number of shares of the Company’s outstanding common stock from approximately 29.5 million shares to approximately 740,000 shares. As a result of the reverse stock split, proportionate adjustments will be made to the number of shares of the Company’s common stock underlying the Company’s outstanding equity awards and warrants and the number of shares issuable under the Company’s equity incentive plans and other existing agreements, as well as the exercise or conversion price, as applicable. There will be no change to the number of authorized shares or the par value per share of the Company’s common stock.

[stock1ace1]

Cnxa .14 break !!

[VVSDiamondHands]

OBLG .46 traded entire o/s after hrs. 3 million outstanding

[stock1ace1]

Bsfc .40 (100%) wow monster mover

[stock1ace1]

Glto .63

[stock1ace1]

ABVC $1.38 Huge news 3 mill o/s -> ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

[stock1ace1]

ABVc 2.12$ been calling this monster out

[stock1ace1]

Big news -> ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

[stock1ace1]

Ai @$28 on gap watch for tomorrow if trend continues will repeat

[stock1ace1]

Abvc $1.92 ripping !!

[stock1ace1]

Ai Squeeze 30$ break ! Ciss @.44 ai play as well should follow

[stock1ace1]

Ai $31.50 Squeeze! Ai Plays On Wartch

[stock1ace1]

Feng has tons of cash woowww! -> https://finviz.com/quote.ashx?t=FENG&p=d

Only @$1.34 has over 25$ per cash a share
13$ book value


Crazy!!!!

https://finviz.com/quote.ashx?t=FENG&p=d

[stock1ace1]

FENG $1.34 **$25Cash/share $13Book/share !!! Per finviz*

Look —-> https://finviz.com/quote.ashx?t=FENG&p=d

https://stockcharts.com/h-sc/ui?s=Feng

[stock1ace1]

Ciss .53 moving !

[stock1ace1]

Theres a reason WBUY went from 14$ to 1$ in 3 days … Pump & Dump at its finest.

[stock1ace1]

Wbuy huge dumps $1.03 new 52 week lows today .. wouldnt touch that even with your own money brother .. stay safe

[stock1ace1]

Crazy $1.9 Billion in cash FENG lets goo !!

12 Million Outstanding
1.9 Billion In Cash


Do the math folks !!!!

[stock1ace1]

WBUY $1.00 new 52 week low like i said sum will just have to learn the hard way…

Hope you recoup your losses brother stay safe :)

[stock1ace1]

Wbuy .91 new 52 week low yikes

[stock1ace1]

Wbuy .82 new 52 week low

[stock1ace1]

Wbuy .75 new 52 week low -31%

[stock1ace1]

Wbuy .71 new 52 week low shorts banking here today ! Down -36%

[stock1ace1]

WBUY .60 new 52 week lows hitting again bulls got trapped once again ..

[stock1ace1]

FENG $1.35 .1.9 Bill cash on balance sheet -> Cash and cash flow
As of December 31, 2022, the Company's cash, cash equivalents, short-term deposits, long-term deposits, short-term investments, short-term restricted cash and long-term restricted cash totaled RMB13,398.8 million (US$1,942.7 million)

[stock1ace1]

Wbuy dumping what happend ?

[stock1ace1]

Welp it safe to say i won Augusta thanks for playing =D

“Quote”

$WBUY 1.16 $FENG 1.40 -- I bet $WBUY will out gain $FENG this week -- let's see which stock has the biggest gain by Friday COB -- WEEKLY GAIN


Feng $1.33 (-7 cents)
Wbuy $.66 (-50 cents)

[stock1ace1]

Wbuy .70s up is it ready to roll?

[stock1ace1]

Watch for $64 break ASO rally continues

[stock1ace1]

Sing fills $1.73 thanks $$$

[stock1ace1]

Sing $1.95 may go here !!!!

[stock1ace1]

Laes $1.39 Hod bust

[stock1ace1]

Laes $1.41 going !!!

[stock1ace1]

Laes $1.44

[stock1ace1]

Sint .40 break red to green ??

[stock1ace1]

Sint .40s Up ** .41 is 50ma break ->https://stockcharts.com/h-sc/ui?s=Sing

[AugustaFriends]

$QSG green slowly continues to rise

[AugustaFriends]

** alert ** $WULF 1.90 break $2.03 target is $3.20 !! #BTC #Bitcoin play




https://schrts.co/MKjjhgmm

[AugustaFriends]

$ROMA Dip buying at $1.15 break of 1.33 soon , maybe tomorrow

[AugustaFriends]

$ADIL 1.78 watch for 1.81 break and we get going

[AugustaFriends]

$LIFW 1.15 break 1.25 we BOOM Orions this is next $AIMD 100% Winner !!!

[AugustaFriends]

$STRC $1.77 an #AI company target $3.25 plus, $NVDA $AMZN $AI $IBM $ARM Sarcos Robotics is Now Palladyne AI


$STRC Sarcos Robotics is Now Palladyne AI

https://finance.yahoo.com/news/sarcos-robotics-now-palladyne-ai-130000968.html

[stock1ace1]

AGRI .17 last run went to .70 few weeks ago on patent news … news watch

5 mill float
15 mill o/s

Per finviz

https://finviz.com/quote.ashx?t=AGRI&p=d

[stock1ace1]

Agri Hod bust a/h $.1848 going

[stock1ace1]

Agri L2 Just cleared mms @.54 & .80 watching for news today

[stock1ace1]

Sxtc Has $30CashPerShare @$1.66 way undervalued only 500k float


$30 Cash per share
500k Float
Per finviz -> https://finviz.com/quote.ashx?t=SXTC&ty=c&ta=1&p=d

https://schrts.co/aqvXXBvK

[stock1ace1]

Sxtc $1.80s breakout Hod Bust !!!

[stock1ace1]

Big bids in angh @$1.02

[stock1ace1]

Chnr $1.25

[stock1ace1]

Elws .73s going

[stock1ace1]

Chnr $1.24s selling dried up L2 ask side super clean

[stock1ace1]

Chnr $1.22 tiny float reversal watch

[stock1ace1]

Chnr $1.23s up

[stock1ace1]

Gcts Halted $7.16

[stock1ace1]

Chnr $1.25s Up on ask thin L2 clear

[stock1ace1]

BA 172$ **10 red days bounce watch

[stock1ace1]

BA big spike intraday !!

[stock1ace1]

BA $168 **** Bounce Watch 11 red days !!

[stock1ace1]

Bq .26 chart setup -> https://schrts.co/wIgNWAZd

[stock1ace1]

Agba $1.84 moving

[stock1ace1]

Awin $3.68 chart -> https://schrts.co/JqSaPfHD

[stock1ace1]

Mrdb .50 -> .60 cent all cash takeover bid ->

Progress Software Considers Possible Offer To Acquire All Of The Debt And The Entire Issued And To Be Issued Capital Of MariaDB

Mentioned:
MRDB — PRGS

Under the Possible Offer, each MariaDB shareholder would be entitled to receive:
$0.60 for each MariaDB share, payable in cash.

[stock1ace1]

Vista Outdoor Shares Rise After It Tells MNC Capital to Raise Offer -- Update
Mentioned: VSTO
By Ben Glickman

Vista Outdoor said Monday it had advised MNC Capital to up its bid to acquire the company as MNC looks to beat out a merger deal between Vista and Czechoslovak Group.

Anoka, Minn.-based Vista said it had provided MNC with certain non-public information, as allowed under its merger with Czech defense company CSG. Vista said it was in discussions with MNC and had advised the firm that it expects to receive a higher offer.

Vista shares rose 6.6% to $34.48. Shares are up about 17% so far this year.

MNC previously bid $37.50 a share in cash for Vista, up from an initial unsolicited offer of $35 a share, The Wall Street Journal reported. The $35-a-share offer valued Vista at $2.9 billion, including debt.

Vista Outdoor said Monday that it does not believe MNC's latest proposal is superior to its deal with CSG, and said it was still bound by the terms of the earlier deal.

Vista already agreed in October to merge its sporting-goods business with CSG in a cash deal valuing the unit at $1.9 billion. The deal followed the company's decision to spin off the business in 2022.

MNC is not the first attempted spoiler for the CSG deal. Firearm maker Colt CZ Group proposed a cash-and-stock deal in November, valuing Vista at $30 a share. That offer was rejected.

Vista's deal with CSG still must be cleared by the Committee on Foreign Investment in the United States, which reviews investments in the U.S. by foreign businesses. The company has previously said it expects the committee, called CFIUS, to make a decision on the deal in a matter of weeks.

The merger has faced skepticism from lawmakers, who cite concerns for national security. Last week, Sen. John Kennedy of Louisiana called on CFIUS to investigate the deal and said it would lead to excessive consolidation in the ammunition market.

Vista said Monday it was still confident it would receive clearance from the committee.

Write to Ben Glickman at [e-mail]

(END) Dow Jones Newswires

April 22, 2024 13:33 ET (17:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.

[stock1ace1]

Verb .185 hod bust

[stock1ace1]

Baba selloff watch (Puts / Shorts)

[stock1ace1]

Baba selling off ! Lod break

[stock1ace1]

IMab ->Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

[stock1ace1]

MRDB .51 Breakout watch

[stock1ace1]

Cphi .32 New Product Launch Watch 1 mill float

***** ONLY 1 month left of first half 2024 news could come any day

Coming 1st Half 2024 ..
—> Dry Eye Disease (DED) therapeutic device

QUOTE from -> 2023 News
“”We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."”

after split 1-for 5 (3/6/24)
1 Million float
10 Mill o/s
Insiders own 86% per finviz*

Chart -> https://schrts.co/EjjTrTmK
Finviz -> https://finviz.com/quote.ashx?t=CPHI&p=d

News —> 11/29/23

China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device

Source: PR Newswire (US)
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.

According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.

This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html

SOURCE China Pharma Holdings, Inc.


Copyright 2023 PR Newswire

[stock1ace1]

Cphi .35s going …

[stock1ace1]

AMC $5.80 Squeeze a/h setting up

[stock1ace1]

Amc $6.00 break squeeze !!!

[stock1ace1]

Amc 8s easy $$$

[knrorrel]

PEGY, FFIE, CRKN-next should b $AKAN , looks to $AGBA

$AMC and GME can be two fantastic fantastic stocks today. which end up in the green after the massive sell-off from the red area. let's see what happens

imho

[stock1ace1]

NCPL .15s Up huge buy just hit

[stock1ace1]

SPCB @.21 & Israel Defense stocks tomorrow —>Iran’s president Raisi crashes

https://www.reuters.com/world/middle-east/helicopter-iranian-presidents-convoy-accident-says-strate-tv-2024-05-19/

[stock1ace1]

Breaking News ->Iran President dead.

( Isreal & Government Defense Stocks On Watch Today. )

Iran's President Raisi dead in helicopter crash, Iranian state media reports

https://abcnews.go.com/amp/International/iran-president-ebrahim-raisi-helicopter-hard-landing-search-underway/story?id=110374228

[stock1ace1]

HUGE BUY ALERT !!! SPCB wow .23s going

[stock1ace1]

Spcb bids filling .2126 :D

[stock1ace1]

Cing .85 breaking out

[stock1ace1]

Cing ->FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Source: GlobeNewswire Inc.

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced that it has received confirmation from and is aligned with the U.S. Food and Drug Administration (FDA) on the requirements necessary for filing a New Drug Application (NDA) for its lead Phase 3 candidate CTx-1301 (dexmethylphenidate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients six years of age or older.
Details from the FDA communication to Cingulate include the following:

Per the 505(b)(2) pathway, submission of CTx-1301’s NDA does not require continuation of the fixed dose study and the onset and duration study;
Data collected to date from these two Phase 3 studies will be included in the filing; and
Contemporaneously with the preparation of the NDA filing, Cingulate will conduct a Phase 1 fed/fast study, the study is expected to last approximately two to three weeks, with the results being included in the NDA filing.
“We are pleased with the FDA’s guidance and perspective regarding our pathway to a timely NDA filing, and we will proceed to complete all remaining requirements accordingly,” said Cingulate Chairman and CEO Shane J. Schaffer. “We also believe this communication provides additional go-to-market momentum as we continue to meet with potential partners for the outlicensing of CTx-1301 in the United States and abroad. Now that we have a clear path to submission, we look forward to engaging with key payer stakeholders to achieve maximum access and market penetration to benefit ADHD patients and their families.”

Cingulate has begun NDA preparation and expects to submit its filing in the first half of 2025.

Ann Childress, M.D., President, Center for Psychiatry and Behavior Medicine, Inc., and lead investigator of Cingulate’s CTx-1301 onset and duration study, stated, “The treatment effect size of CTx-1301 was remarkable given the current effect sizes observed in the marketplace. Many patients require longer duration of efficacy and must add a second, or booster, dose to ensure treatment effect over their entire active day. The patients I observed, once notified they were taking CTx-1301, have expressed a desire to remain on the medication after the trial concluded.”

“If approved,” Childress continued, “I believe CTx-1301 could potentially benefit the more than 60 percent of patients currently using immediate-release booster doses to extend the efficacy of their medications.”

Earlier this year, Cingulate presented results from the Phase 3 adult efficacy and safety study of CTx-1301 at the 2024 American Professional Society of ADHD and Related Disorders (APSARD) conference in Orlando, FL.

The results were previously presented at the 2023 Psych Congress, where a poster describing the data was selected as a finalist for the Psych Congress’s First Annual Poster Awards.

The Cingulate poster presented at APSARD provided additional insight regarding CTx-1301’s ADHD leading effect size. Effect size conveys clinical significance rather than statistical significance, is not reliant on sample size, and allows for comparison across trials. The poster presented may be viewed here.

About Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., approximately 6.4 million children and adolescents (11 percent) aged under the age of 18 have been diagnosed with ADHD. Among this group, approximately 80 percent receive treatment, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Adult ADHD prevalence is estimated at approximately 11 million patients (4.4 percent), almost double the size of the child and adolescent segment combined. However, only an estimated 20 percent receive treatment.

About CTx-1301
Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. While stimulants are the gold standard of ADHD treatment due to their efficacy and safety, the long-standing challenge continues to be providing patients with an entire active-day duration of action. CTx-1301 is designed to precisely deliver three releases of medication at the predefined time, ratio, and style of release to optimize patient care in one tablet. The result is a rapid onset and entire active-day efficacy, with the third dose being released around the time when other extended-release stimulant products begin to wear off.

About Precision Timed Release™ (PTR™) Platform Technology
Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the core tablet. The EBL formulation, Oralogik™, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition to Anxiety and ADHD where one or more active pharmaceutical ingredients need to be delivered several times a day at specific, predefined time intervals and released in a manner that would offer significant improvement over existing therapies. To see Cingulate’s PTR Platform, click here.

About Cingulate®
Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of attention deficit/hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
Cingulate is headquartered in Kansas City. For more information visit Cingulate.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on April 1, 2024. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Investor Relations
Thomas Dalton
Vice President, Investor & Public Relations, Cingulate
[e-mail]
913-942-2301

Matt Kreps
Darrow Associates
[e-mail]
214-597-8200

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/00c8b334-57ec-49cf-9a59-02d75463089e

[stock1ace1]

Cing green watch for 20/50ma cross @.94

[stock1ace1]

Cing .73s were filling dip N Rip !!

[stock1ace1]

Ifbd nice 20/50ma cross -> https://schrts.co/yVunDqdx

[stock1ace1]

Ifbd $4.30 40$ mill in cash 1.3 mill o/s could go parabolic after 5.00$ break

[stock1ace1]

Ncpl wants .13s and to go green

[stock1ace1]

Holo was $2.10

[stock1ace1]

Bdrx .95 Data phase 2 coming jun 22th

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis (“FAP”) are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain on June 22, 2024. Carol Burke, MD, the Principal Investigator, will present the six and 12 month data (NCT04230499) in an oral presentation at the meeting. Dr Burke presented the six-month data at the Digestive Disease Weekly meeting in Washington D.C. on May 21, 2024.

[stock1ace1]

JFBR .45 ***+ Squeeezeee !!!!

[stock1ace1]

Jfbr .50 break

[stock1ace1]

Wnw $.99

[AugustaFriends]

$MITQ break .70 should run JMHO

[stock1ace1]

Nutz ! Rvyl @$1.56 W/ $13 Cash per share ($88 Million In Cash / 6 Mill o/s ) !!!!


https://finviz.com/quote.ashx?t=RVYL&p=d

Last 10q
Cash and cash equivalents
$ 10,523,000

Restricted cash
$ 78,293,000

[Jaxxm]

FFIE crazy today, then VHAI, .07

[stock1ace1]

TSBX $2.95 … watch for $3.00 break !

[stock1ace1]

Intc $31.19 Chart 20/50ma. Break—> https://schrts.co/FXjHUXHN

[AugustaFriends]

$VHAI opinions on this one Orions

[AugustaFriends]

$MITQ .65 on watch for a .70 TRIGGER -- could get it going

[stock1ace1]

Serv $2.69

[stock1ace1]

RR $1.46 Richtech robotics

[Jaxxm]

TKLF(.61)~$196 Million Rev, $7.5 Million Net Profit, 42 million Outstanding shares.. VERY UNDERVALUED

Fiscal Year 2024 Financial Highlights

Total revenue was $195.7 million for fiscal year 2024, increased by 15.3% from $169.7 million for fiscal year 2023.

Income from operations was $5.8 million for fiscal year 2024, increased by 601.3% from $0.8 million for fiscal year 2023.

Net income increased to $7.5 million for fiscal year 2024, compared to net loss of $8.0 million for fiscal year 2023.

Net cash provided by operating activities increased to $1.9 million for fiscal year 2024, from net cash used in operating activities of $25.7 million for fiscal year 2023.

Basic and diluted earnings per share was $0.20 for fiscal year 2024, compared to loss per share of $0.22 for fiscal year 2023.

https://finance.yahoo.com/news/yoshitsu-co-ltd-reports-fiscal-120000253.html

[stock1ace1]

Brea .74

[stock1ace1]

Sxtc $1.18 going !!

[stock1ace1]

Sxtc $1.12

[stock1ace1]

Rvyl $1.80 -> $13 cash/share on balance sheet per finviz .

[Jaxxm]

SLNA .045 pre-market skyrocketing

[Jaxxm]

BFI once was $15, float 12.7 million, outstanding shares 27.4 million burger and pizza franchise company.

BFI 43.8% of shares hold by insiders 17% of shares by institutions

BFI outstanding shares 27.4 million

Revenue per share 6.34 dollars

https://finance.yahoo.com/quote/BFI/key-statistics/

[Jaxxm]

BFI~ 20% up volume increases reversal started Burgerfi company once was 15 dollars share price 14 milliontiny float

[Jaxxm]

BFI .38 pre-market green

[stock1ace1]

“HUGE” .08 ticker name changed to QNTM webull says 610k float ????

This could get interesting …

[Jaxxm]

VHAI(.05)~24/7 AI-powered phone service in 55 languages.

Exciting News from Vocodia: Our IR DISA is now available for public companies. This 24/7 AI-powered phone service elevates investor relations by ensuring every call is answered at any time, with human-like interaction in 55 languages. Link in bio. $VHAI

Exciting News from Vocodia: Our IR DISA is now available for public companies. This 24/7 AI-powered phone service elevates investor relations by ensuring every call is answered at any time, with human-like interaction in 55 languages. Link in bio. $VHAI
.#IRDISA #DISA #Vocodia pic.twitter.com/DHSI4hG8Uj

— Vocodia (@TheVocodia) August 22, 2024

🚀 We’ve got something exciting in the works here at Vocodia ($VHAI). Final touches are being made, and we can’t wait to share the news with you soon. Stay tuned for what’s next in conversational AI. 
.
.#Vocodia #Innovation #VocodiaHoldings #ConversationalAI #HumanizedAI #VHAI pic.twitter.com/d6jeL9LUr8

— Vocodia (@TheVocodia) August 20, 2024